Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 722 | 123 | 583 |
| Samples | 671 | 118 | 544 |
| Peptides | 436 | 80 | 383 |
Function
KCNA5 · Potassium voltage-gated channel subfamily A member 5
Potassium channels represent the most complex class of voltage-gated ino channels from both functional and structural standpoints. Their diverse functions include regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, and cell volume. Four sequence-related potassium channel genes - shaker, shaw, shab, and shal - have been identified in Drosophila, and each has been shown to have human homolog(s). This gene encodes a member of the potassium channel, voltage-gated, shaker-related subfamily. This member contains six membrane-spanning domains with a shaker-type repeat in the fourth segment. It belongs to the delayed rectifier class, the function of which could restore the resting membrane potential of beta cells after depolarization and thereby contribute to the regulation of insulin secretion. This gene is intronless, and the gene is clustered with genes KCNA1 and KCNA6 on chromosome 12. Defects in this gene are a cause of familial atrial fibrillation type 7 (ATFB7). [provided by RefSeq, May 2012].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000252321 | P22460 | 722 | 436 |
Gene Properties
Recurrent Mutations
All 436 amino-acid changes on canonical ENST00000252321 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in KCNA5 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in KCNA5 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 3/40 8% | 0/0 0% |
| Endometrial Carcinoma | 8/42 19% | 33/612 5% |
| Acute Myeloid Leukemia | 4/90 4% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Melanoma | 9/210 4% | 65/1899 3% |
| Non-Small Cell Lung Carcinoma | 15/304 5% | 40/1390 3% |
| Colorectal Carcinoma | 13/143 9% | 93/3239 3% |
| Gastric Carcinoma | 3/74 4% | 55/1809 3% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 23/810 3% |
| Neuroendocrine Tumour | 16/154 10% | 4/577 1% |
| Bladder Carcinoma | 3/58 5% | 18/956 2% |
| Rhabdomyosarcoma | 2/33 6% | 2/171 1% |
| Biliary Tract Carcinoma | 0/54 0% | 18/950 2% |
| Cervical Carcinoma | 3/35 9% | 5/422 1% |
| Hodgkins Lymphoma | 1/16 6% | 1/122 1% |
| Non-Cancerous | 0/104 0% | 12/830 1% |
| Hepatocellular Carcinoma | 0/46 0% | 28/2210 1% |
| Other Solid Cancers | 0/94 0% | 20/1515 1% |
| Other Sarcomas | 3/69 4% | 6/699 1% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 7/752 1% |
| Ewings Sarcoma | 3/63 5% | 0/262 0% |
| Mesothelioma | 1/62 2% | 1/165 1% |
| Glioma | 0/52 0% | 19/2127 1% |
| Thyroid Gland Carcinoma | 2/45 4% | 12/1592 1% |
| Pancreatic Carcinoma | 2/89 2% | 12/1611 1% |
| Head and Neck Carcinoma | 3/85 4% | 10/1574 1% |
| Meningioma | 0/3 0% | 2/252 1% |
| Breast Carcinoma | 3/144 2% | 20/3264 1% |
Mutation Distribution
Where KCNA5 is mutated · all tissues, split by cell line vs tissue
How many mutations in KCNA5 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 53 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 722 mutations in KCNA5
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|